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Purpose: It has been proposed that cytokine gene polymorphisms can predispose individuals to disease by enhancing
inflammatory  processes.  Considering  the  relevance  of  interleukin-1  (IL-1)  in  the  pathogenesis  of  toxoplasmic
retinochoroiditis (TR), we investigated whether IL1A −889 C/T and IL1B +3954C/T promoter polymorphisms are
associated with TR in humans.
Methods: We performed a cross-sectional study that involved 100 Brazilian TR patients and 100 age- and gender-matched
control subjects. Genomic DNA was obtained from oral swabs of all participants and amplified using polymerase chain
reaction (PCR) with specific primers flanking the locus −889 of IL1A and +3954 of IL1B. PCR products were submitted
to digestion and analyzed by PAGE to distinguish C and T alleles.
Results: There was no significant difference in the genotype or allele distributions of the IL1A −889 C/T and IL1B
+3954C/T polymorphisms in patients with TR when compared with controls. However, in a subgroup analysis, the
frequency of genotype and allele distributions of IL1A −889 C/T differed significantly between TR patients with and
without recurrent episodes.
Conclusion: This study suggests that the genotypes related with a high production of IL-1a may be associated with the
recurrence of TR.
Toxoplasmic retinochoroiditis (TR) is the most common
cause  of  posterior  uveitis  in  many  parts  of  the  world,
especially  in  Brazil  [1].  TR  results  in  inflammation  and
dysfunction  of  the  retina,  occasionally  leading  to  loss  of
vision. The intensity of damage to the retina and choroid
depends on the severity of the infection and of the associated
inflammatory reaction [1,2].
While several mediators influence the development of
inflammatory responses, interleukin-1 (IL-1) is likely to play
a  major  role  in  these  processes  [3].  Produced  mainly  by
activated  mononuclear  cells,  IL-1  is  responsible  for  the
induction of adhesion molecules on endothelial cells, thereby
facilitating the migration of leukocytes from blood vessels
into inflamed tissue [4].
There  is  considerable  evidence  obtained  from
experimental  data  and  from  studies  involving  humans  to
suggest a relevant role for IL-1 in the pathogenesis of TR. For
instance, acquired TR patients have been found to present
higher  levels  of  IL-1  than  asymptomatic  subjects  [5].
Additionally,  human  retinal  pigmented  epithelial  cells
inoculated with Toxoplasma gondii increase their production
of IL-1β, IL-6, granulocyte-macrophage colony-stimulating
factor  (GM-CSF),  and  intercellular  adhesion  molecule
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(ICAM)  [6].  Elevated  production  of  these  factors  may
contribute to the local inflammatory response during primary
infections or during recurrent episodes of toxoplasma-induced
retinochoroiditis [6].
The IL-1 family consists of three homologous proteins:
IL-1α and IL-1β, which are pro-inflammatory proteins, and
IL-1  receptor  antagonist  (IL-1ra),  a  molecule  with
antiinflammatory properties. These proteins are encoded by
the genes IL1A, IL1B, and IL1RN, respectively, which are
clustered on chromosome 2q13–21 and are polymorphic in
several loci [7,8]. Single nucleotide polymorphisms in the
IL-1  locus,  their  functional  consequences,  and  their
association with susceptibility and severity of inflammatory
diseases  have  been  discussed  in  the  literature  [9,10].  For
instance,  the  severity  of  periodontal  disease  has  been
positively associated with carriage of allele T at position -889
of the IL-1A gene [11].
Several studies have shown the functional relevance of
the  promoter  region  of  IL1A  for  the  regulation  of  IL-1
expression  [10-12].  The  C/T  single  base  variation  was
described in the −889 locus of the IL1A promoter, with the
allele T being associated with a fourfold increase of IL-1α
expression [11]. This suggests a mechanism whereby this
genetic  polymorphism  acts  to  modulate  IL-1alpha  protein
production  and  may  influence  the  pathogenesis  of
inflammatory diseases, including periodontal disease [11].
Additionally,  the  IL1A  (−889)  CC  genotype  has  been
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1845associated with a significantly lower transcriptional activity
of  the  gene  and  lower  plasmatic  levels  of  IL-1α,  when
compared with the TT genotype [10].
A polymorphism in the +3954 locus of IL1B has been
associated  with  an  increased  production  of  IL-1β.
Homozygous individuals for the T allele produce a fourfold
higher amount of IL-1β compared to individuals displaying
the  CC  genotype  [13].  This  genetic  mediated  cytokine
production  may  explain  why  some  subjects  have  a  more
vigorous  inflammatory  response  than  others  to  the  same
stimulus [14].
We hypothesized that the presence of polymorphic alleles
(T), related to the expression of higher levels of IL-1α and
IL-1β,  may  be  associated  with  the  occurrence  of  TR.
Therefore, our aim was to investigate the possible association
between IL1A (−889) and IL1B (+3954) polymorphisms and
TR in humans.
METHODS
Subjects: This study protocol adhered to the tenets of the
Declaration  of  Helsinki  and  was  approved  by  the  local
Institutional Review Board. Patients were informed verbally
and in writing of the potential benefits and risks of the study,
and all patients signed a written consent form.
Between August and November 2006, 100 patients (41
males, 59 females) with diagnosed TR were recruited from
the Uveitis Section, Department of Ophthalmology, Federal
University of Minas Gerais - Brazil,. All patients underwent
a  detailed  ocular  examination,  including  corrected  visual
acuity, applanation tonometry for intraocular pressure, slit
lamp examination, a fundus examination with 78 D lens and
indirect  ophthalmoscope.  The  number  and  location  of
retinochoroidal lesions were documented for all patients by
fundus drawings or photographs. Active TR was defined by
the presence of gray-white focus of retinal necrosis next to a
pigmented retinal scar in patients with positive serology for
toxoplasmosis. Recurrent disease was defined as a new active
focus  of  retinal  necrosis  after  three  months  of  an  active
episode [15].
Additionally recruited were 100 healthy donors from the
Hemominas  Foundation,  Belo  Horizonte,  Brazil.  These
donors  were  matched  by  age  and  gender  and  served  as
controls.  All  controls  had  a  positive  IgG  antibody  for
toxoplasmosis and no history of uveitis. Each control was
given an ocular examination to exclude the presence of retinal
scars.
Sample collection and DNA extraction: Epithelial cells were
collected from all patients and controls by buccal swab. Each
plastic  spatula  used  to  harvest  the  cells  was  placed
immediately in 1500 μl of Krebs buffer, which contained 20%
NaCl, 2% KCl, 2% CaCl2, 2% H2O, MgSO4, KH2PO4, and
C6H12O6. DNA extraction was then performed. A pellet of
cells was obtained by centrifugation at 200x g for 5 min. The
supernatant was removed. Next, 20 μl of silica (Sigma, St.
Louis, MO) and 450 μl of lysis buffer, which consisted of 6.0
M guanidinium thiocyanate (GuSCN) 65 mM Tris, pH 6.4, 25
mM  EDTA,  and  1.5%  Triton  X-100,  were  added  to  the
microtubes. Samples were homogenized and 98 incubated for
30  min  at  56  °C.  Next,  samples  underwent  another
centrifugation, and the supernatant was discharged. The pellet
obtained (with DNA adsorbed on the silica) was washed twice
with 450 μl washing buffer that consisted of 6.0 M GuSCN
and 65 mM Tris, pH 6.4. twice with 450 μl of 70% ethanol,
once with 450 μl acetone, and then dried at 56 °C for 20 min.
Finally, 100 μl of Tris-EDTA (TE) buffer, which contained
10 mM Tris, pH 8.0 and 1 mM EDTA, was added, and the
supernatant was incubated at 56 °C for 12 h to release the
DNA.  After  incubation,  the  solution  was  homogenized,
centrifuged,  and  the  supernatant  containing  DNA  was
transferred to a new tube.
Polymerase  chain  reaction  and  restriction  endonuclease
digestion: The IL1A (−889) polymorphism (Gene ID 3552)
was  assessed  after  polymerase  chain  reaction  (PCR)
amplification and digestion. The sequences of PCR primers
used were as follows: 5'-AAG CTT GTT CTA CCA CCT
GAA CTA GGC-3' and 5'-TTA CAT ATG AGC CTT CCA
TG-3', with an expected PCR product size of 99 bp for the
IL1-α polymorphism [7]; and 5'-AGG CAA TAG GTT TTG
AGG GCC AT-3' and 5'-TCC TCC CTG CTC CGA TTC
CG-3', with an expected PCR product size of 194 bp for the
IL1β polymorphism (Gene ID 3553), as previously described
[16]. PCR was performed in a total volume of 50 μl, which
contained  10  μl  of  DNA  solution,  20  pmol  primers  per
reaction, and a premix buffer that consisted of 50 mM KCl,
10 mM Tris, pH 8.4, 0.1% Triton X-100, 1.5 mM MgCl2,
deoxynucleoside triphosphates, and Taq DNA polymerase.
The amplification conditions consisted of 94 °C for 3 min,
followed by 45 cycles of 94 °C for 30 s, 56 °C for 35 s, and
72 °C for 30 s. The run was terminated by a final elongation
at 72 °C for 5 min. For IL-1A polymorphism, 5U of NcoI
enzyme was used and the digestion products obtained were C
(83+16bp) and T (99 bp) alleles. For IL-1B polymorphism,
5U  of  TaqI  enzyme  was  used  and  the  digestion  products
obtained were C (97+85+12 bp) and T (182+12 bp) alleles.
The visualization of the digestion products was done in a 10%
acrylamide gel electrophoresis stained with silver nitrate.
Statistical analysis: The study groups were tested for Hardy–
Weinberg equilibrium by comparing the expected with the
observed genotype frequencies.
Statistical analyses were performed using the SPSS for
Windows (11.0.1; SPSS, Inc., Chicago, IL). Associations with
TR  were  investigated  between  genotype  and  allelic
frequencies. χ2 analysis and calculation of odds ratio (OR)
with 95% confidence interval were performed. The level of
statistical significance was set at p<0.05.
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We  analyzed  genotype  and  allele  distributions  of  the
IL1A-889 C/T polymorphism in controls. No difference was
found  between  observed  and  expected  distributions  of
genotypes  for  control  subjects  and,  therefore,  it  was
considered to be in Hardy–Weinberg equilibrium. There was
no significant difference in the genotype (χ2=2.58; p=0.28) or
allele  (χ2=1.91;  p=0.17)  distribution  in  patients  with  TR
compared with controls (Table 1). A subgroup analysis was
performed involving only patients with one or more years of
follow-up (n=59; Table 2). The mean follow-up did not differ
significantly  between  patients  with  (7.4±3.4  years)  and
without (6.7±8.6 years) previous TR episodes (p=0.10). The
frequencies of the genotype (χ2=5.71, p=0.03) and of the
allele (χ2=5.46, p=0.02) distributions differed significantly
when comparing TR patients with and without recurrence of
the disease. The CT genotype and T allele were associated
with the recurrence of TR.
As  for  IL1B  +3954  C/T  polymorphism  analysis,  no
difference  was  found  between  observed  and  expected
distributions of genotypes for the control group and therefore
it  was  considered  to  be  in  Hardy–Weinberg  equilibrium.
There was no significant difference in the genotype (χ2=3.12;
p=0.21) or allele (χ2=1.92; p=0.17) distribution in patients
with  TR  compared  with  control  subjects  (Table  1).  The
frequencies  of  the  genotype  (χ2=2.55;  p=0.28)  and  allele
(χ2=1.67; p=0.19) distributions did not significantly differ
between  TR  patients  with  and  without  recurrent  disease
(Table 2).
DISCUSSION
In our study, we found that recurrence of TR is associated with
IL1A −889 C/T polymorphism. The CT genotype and T allele
TABLE 1. DISTRIBUTION OF THE IL1A (-889) AND IL1B (+3954) GENOTYPES AND
ALLELE BETWEEN TOXOPLASMOSIS RETINOCHOROIDITIS PATIENTS AND CONTROL SUBJECTS
Polymorphism
TR
n
Control
n χ2 p
IL1A
Genotype
CC 48 42 2.58 0.28
CT 44 43
TT 8 15
Allele
C 140 127 1.91 0.17
T 60 73
IL1B
Genotype
CC 49 61 3.12 0.21
CT 46 34
TT 5 5
Allele
C 144 156 1.92 0.17
T 56 44
Distribution of the IL1A (-889) and IL1B (+3954) genotypes
and  allele  between  toxoplasmosis  retinochoroiditis  (TR)
patients (n=100) and control subjects (n=100).
were associated with TR recurrence. This link between TR
and  a  genotype  or  allele  associated  with  a  high  IL-1α
production provides evidence that abnormalities in the genetic
control of cytokine levels may be relevant in influencing the
immune response in TR.
The inflammatory response in uveitis is controlled by a
series of mediators including cytokines that seem to be locally
produced in aqueous humor [16]. Cytokine production has
been shown to be under genetic control. Polymorphisms in
cytokine  genes  may  influence  the  susceptibility  to
inflammatory  diseases  or  their  severity.  In  line  with  our
results, a previous study found that −889 T IL1A allele, related
with  higher  IL-1α  production,  was  associated  with  the
development of chronic iridocyclitis in juvenile rheumatoid
arthritis patients [17]. However, Cimaz, et al. [18] found no
association when they investigated the genetic contribution of
IL1B  +3954  C/T  polymorphism  on  uveitis  occurrence  in
juvenile rheumatoid arthritis patients.
There is evidence that IL1A and IL1B polymorphisms
may  be  in  linkage  disequilibrium  [19]  and  that  the  TT
genotype of the IL1A −889 C/T polymorphism influences
circulating levels of IL-1β [20]. However, in the present study,
we did not find an association between IL1B +3954 C/T
polymorphism and TR recurrence.
To date, few studies have analyzed the association of
cytokine polymorphisms and TR. A previous study performed
by us showed that the IL10 −1082 A allele was associated with
TR occurrence [21]. This allele is associated with intermediate
or lower IL-10 production. Regarding IL-10 as a major anti-
inflammatory cytokine, this result suggests that TR seemed to
occur  in  patients  who  may  have  problems  in  controlling
TABLE 2. DISTRIBUTION OF THE IL1A (-889) AND IL1B (+3954) GENOTYPES AND
ALLELE IN TOXOPLASMOSIS RETINOCHOROIDITIS PATIENTS WITH AND WITHOUT RECURRENT
EPISODES
Recurrence Yes No
Polymorphism n n χ2 p
IL1A
Genotype
CC 14 9 6.83 0.03
CT 25 5
TT 6 0
Allele
C 53 23 5.46 0.02
T 37 5
IL1B
Genotype
CC 21 9 2.55 0.28
CT 21 5
TT 3 0
Allele
C 63 23 1.67 0.19
T 27 5
Distribution of the IL1A (-889) and IL1B (+3954) genotypes
and allele in toxoplasmosis retinochoroiditis (TR) patients
followed for one or more years who presented (Yes; n=35) or
(No; n=14) further recurrence of the disease.
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present results, TR may recur in patients prone to develop a
more intense inflammation. Thus, a high inflammatory profile
may be linked with occurrence as well as recurrence of TR.
Together these results provide evidence for the role of genetic
control of cytokine levels in the pathogenesis of TR.
This  study  is  the  first  to  demonstrate  the  association
between the genetic polymorphism and recurrence of TR in
humans. Recurrence rates vary greatly. The confirmation of a
role for IL-1α in TR will require larger cohorts of patients,
longer follow-up, and the analysis of other polymorphisms or
haplotypes.
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